Monte Rosa Therapeutics, Inc. Public Float
Monte Rosa Therapeutics, Inc. (GLUE) had Public Float of $212.00 million as of 2025-06-30, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Cover Page
dei:EntityPublicFloat · last filed 2026-03-17
- 2025-06-30: Entity Public Float $212.00M.
- 2024-06-30: Entity Public Float $199.00M.
- 2023-06-30: Entity Public Float $234.30M.
- 2022-06-30: Entity Public Float $302.60M.
| Period end | Entity Public Float |
|---|---|
| 2025-06-30 | $212.00M 10-K · filed 2026-03-17 |
| 2024-06-30 | $199.00M 10-K · filed 2025-03-20 |
| 2023-06-30 | $234.30M 10-K · filed 2024-03-14 |
| 2022-06-30 | $302.60M 10-K · filed 2023-03-16 |
| 2021-06-30 | $654.70M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |